Vortioxetine for Health & Longevity

Evidence Review created on 11/20/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Trintellix, Brintellix, Lu AA21004, Vortioxetine Hydrobromide

Motivation

Vortioxetine (sold as Trintellix in the United States and Brintellix in Europe) is a prescription antidepressant approved for major depression in adults. It blocks the recycling of the brain messenger serotonin and also acts directly on several serotonin receptors, a combination that sets it apart from the most widely used antidepressants. It draws interest beyond mood because it was tested on thinking speed and memory, not only on sadness and loss of interest.

Depression in midlife and later life is studied as a factor in physical health, mental decline and lifespan, which makes its treatment relevant to adults focused on a long, healthy life. Vortioxetine has been studied in older adults and in people with memory complaints, which drew attention to it as a possible option for keeping the brain sharp with age.

This review examines the evidence on vortioxetine’s effects on mood, thinking and daily function, its side effects and drug interactions, how it is dosed, stopped and monitored, and where research is heading, for health-focused adults comparing it with other options.

Benefits - Risks - Protocol - Conclusion

High-level narrative reviews covering vortioxetine’s pharmacology, cognitive research and clinical use.

Peter Attia’s podcast mentions vortioxetine only briefly, when Sharon Parish names it among antidepressants with fewer sexual side effects (transcript excerpt of #259 – Women’s sexual health), without an overview, so it is not listed. Life Extension’s Depression and Depressive Disorders protocol names vortioxetine only as a recent addition to the antidepressant options, without discussing it in depth, so it is not listed either. No content on vortioxetine was found from Rhonda Patrick, Andrew Huberman, Chris Kresser or Lifespan.io; these sources focus mainly on lifestyle and supplements and have not covered this prescription antidepressant.

Grokipedia

  • Vortioxetine

    An encyclopedic overview of approval history, receptor profile, dosing and trial results; useful as a quick orientation, though it is a secondary summary rather than a primary source.

Examine

No Examine article on vortioxetine exists. Examine.com does not typically cover prescription medications.

ConsumerLab

No ConsumerLab article on vortioxetine exists. ConsumerLab does not typically cover prescription medications.

Systematic Reviews

Systematic reviews and meta-analyses (pooled statistical analyses of several trials) on vortioxetine’s antidepressant effect, cognitive effect and side effects.

Mechanism of Action

A review reports that vortioxetine blocks the serotonin transporter (the protein clearing serotonin from nerve-cell junctions) and acts on several serotonin (5-HT) receptors: it blocks 5-HT3, 5-HT7 and 5-HT1D, partly stimulates 5-HT1B and stimulates 5-HT1A (Sanchez 2015). In rats this raises serotonin, noradrenaline, dopamine, acetylcholine, histamine and glutamate signaling in mood- and memory-related brain regions (Sanchez 2015); blocking 5-HT3 receptors on inhibitory GABA (gamma-aminobutyric acid, the brain’s main calming messenger) neurons is proposed to release cortical activity, underlying the cognitive findings (Sanchez 2015).

A competing reading holds that transporter blockade, shared with selective serotonin reuptake inhibitors (SSRIs, antidepressants that only block serotonin recycling), does most of the work. The US label states the receptor actions’ contribution is not established (Trintellix label), and a PET (positron emission tomography, a brain-imaging scan) study in healthy people found no significant 5-HT1A receptor binding at 30 mg (Stenkrona 2013).

Key pharmacological properties:

  • Half-life: about 66 hours (Trintellix label); steady state (stable blood levels) within two weeks (Trintellix label)
  • Distribution: volume of distribution about 2,600 L (extensive tissue uptake) (Trintellix label); 98% bound to plasma protein (Trintellix label); oral bioavailability (share of a dose reaching the blood) 75% (Trintellix label)
  • Metabolism: oxidation mainly by CYP2D6 (a liver enzyme that breaks down many drugs) to an inactive metabolite, with minor roles for other enzymes (CYP3A4/5, CYP2C19, CYP2C9, CYP2A6, CYP2C8, CYP2B6) (Trintellix label); CYP2D6 poor metabolizers (people with inherited low CYP2D6 activity) carry about twice the plasma level (Trintellix label)

Historical Context & Evolution

Vortioxetine was discovered by Lundbeck under the code Lu AA21004 and developed with Takeda for major depressive disorder (MDD, persistent low mood with loss of interest lasting at least two weeks) and generalized anxiety disorder (GAD, chronic excessive worry). A later meta-analysis found inconsistent anxiety-trial results (Pae 2015); approval covers depression only (Trintellix label). The US Food and Drug Administration (FDA) first approved it in 2013 (Trintellix label), and the European Medicines Agency (EMA) authorized it as Brintellix (EMA SmPC Brintellix).

Its route toward health optimization came through cognition. Manufacturer-funded trials reported faster processing speed in depressed adults that was largely independent of mood change (McIntyre 2014; Mahableshwarkar 2015), and the US label now presents these results without a separate cognitive indication (Trintellix label). Academic groups then tested it in older adults with age-related cognitive decline, funded by a Takeda and Lundbeck grant (Lenze 2020), and in post-COVID-19 condition (persistent symptoms after coronavirus infection), funded by a Lundbeck grant (McIntyre 2024), and laboratory screening flagged it against brain tumor cells (Lee 2024).

Opinion has moved in both directions. An independent Cochrane review found benefit over placebo but rated the evidence low quality and found no advantage over serotonin-noradrenaline reuptake inhibitors (SNRIs, antidepressants that block both serotonin and noradrenaline recycling) (Koesters 2017), while a large network comparison placed it among the better-tolerated, more effective options (Cipriani 2018). Because most trials were funded by Lundbeck and Takeda, independent replication of the cognitive findings remains the open question.

Expected Benefits

High 🟩 🟩 🟩

Relief and Relapse Prevention of Major Depression ⚠️ Conflicted

Vortioxetine reduces depressive symptoms in adult MDD, including at a mean age of 70.6 years in a Lundbeck trial (Katona 2012), per Lundbeck-Takeda trial pools (Thase 2016) and independent syntheses by Koesters (Koesters 2017) and Cipriani (Cipriani 2018). In remitted (symptom-free) patients, continuing it lowered relapse versus placebo in Lundbeck and Takeda trials (Boulenger 2012; Thase 2022). A 600-patient Takeda trial of 5 mg found no difference from placebo (Jain 2013); Cochrane rated evidence quality low (Koesters 2017). Net reading: pooled trials show consistent benefit despite individual negative trials.

Magnitude: MADRS (Montgomery-Åsberg Depression Rating Scale, a clinician-rated depression score) 2.94 points lower than placebo (95% CI, the confidence interval within which the true effect likely lies, −4.07 to −1.80) (Koesters 2017); relapse 13% versus 26% with placebo, hazard ratio (relative rate of relapse over time) 2.01 for placebo versus vortioxetine (95% CI 1.26 to 3.21) (Boulenger 2012).

Medium 🟩 🟩

Processing Speed and Cognitive Function ⚠️ Conflicted

In depressed adults, vortioxetine improved processing speed on the DSST (Digit Symbol Substitution Test, a timed symbol-matching task) in manufacturer-funded trials led by McIntyre (McIntyre 2014) and Mahableshwarkar (Mahableshwarkar 2015), largely independent of mood. A meta-analysis of six trials agreed (Huang 2022). In adults 65 and older with age-related decline, adding vortioxetine to cognitive training beat placebo only at week 12 (Lenze 2020); in post-COVID-19 condition the primary DSST outcome did not differ from placebo (McIntyre 2024). Net reading: a modest benefit within depression; inconsistent results outside it.

Magnitude: Composite cognition z-score (standard-deviation units combining processing speed and verbal memory) improved 0.36 (95% CI 0.22 to 0.50; 10 mg) and 0.33 (95% CI 0.19 to 0.47; 20 mg) units more than placebo at 8 weeks (McIntyre 2014).

Sexual Function After Switching From an SSRI

In adults whose depression had responded to citalopram, paroxetine or sertraline but who had treatment-emergent sexual dysfunction (sexual problems caused by the drug), switching to vortioxetine improved sexual functioning more than switching to escitalopram, with similar mood control (Jacobsen 2015). This is a single Takeda-sponsored trial; a separate trial in healthy adults from the same sponsor found sexual impairment with paroxetine but not with vortioxetine (Jacobsen 2019).

Magnitude: CSFQ-14 (Changes in Sexual Functioning Questionnaire, 14 items) total score improved 8.8 points with vortioxetine versus 6.6 points with escitalopram after 8 weeks, a 2.2-point difference (P = 0.013, P being the probability that a difference this large arises by chance) (Jacobsen 2015).

Daily Functioning

In a Lundbeck- and Takeda-funded meta-analysis of nine 6–8-week trials in MDD, vortioxetine 10 and 20 mg improved functioning in work, social and family life on the SDS (Sheehan Disability Scale, a self-rated impairment score) more than placebo (Florea 2017), and more patients reached functional remission (near-normal daily functioning) (Florea 2017). The 5 and 15 mg doses did not separate from placebo (Florea 2017). The evidence comes from one sponsor’s trial program.

Magnitude: SDS total score 1.68 (10 mg) and 1.94 (20 mg) points lower than placebo at study end (Florea 2017).

Low 🟩

Anxiety Symptoms ⚠️ Conflicted

In high-anxiety depression, a Takeda- and Lundbeck-funded analysis of 10 trials found lower anxiety scores (Baldwin 2016). In GAD, a four-trial meta-analysis found a small benefit (Pae 2015); a later one pooling different trials and doses found no response benefit (Qin 2019). Net reading: anxiety relief is clearest alongside depression.

Magnitude: HAM-A (Hamilton Anxiety Rating Scale) total 2.04 points lower than placebo at 10 mg in high-anxiety depression (Baldwin 2016); in GAD, response OR (odds ratio, the odds of response relative to placebo) 1.05 (95% CI 0.76 to 1.46) at 10 mg (Qin 2019).

Speculative 🟨

Synaptic Protection in Neurodegeneration Models

In Alzheimer’s-model mice, vortioxetine improved memory and raised synaptic proteins (proteins of nerve-cell connections) without reducing amyloid plaques (protein clumps typical of Alzheimer’s disease) (Jiang 2020). The basis is animal data only.

Anti-Glioblastoma Activity

In tumor tissue from patients with glioblastoma (an aggressive brain cancer), vortioxetine suppressed cancer cells and worked with standard chemotherapy in living animals (Lee 2024). No human outcome data exist.

Benefit-Modifying Factors

  • CYP2D6 genotype: Poor metabolizers carry about twice the plasma level of extensive metabolizers (people with normal CYP2D6 activity) (Trintellix label); whether this changes benefit has not been studied, but the 10 mg ceiling limits the dose range available to them.

  • Baseline inflammation: In post-COVID-19 condition, a processing-speed benefit appeared only with CRP (C-reactive protein, a blood marker of inflammation) above the mean (McIntyre 2024); in depression, adding the anti-inflammatory celecoxib gave no extra benefit (Baune 2021).

  • Baseline anxiety and severity: A sponsor meta-analysis found antidepressant effects held in depression with high anxiety (Baldwin 2016); in GAD, a meta-analysis found people with severe baseline anxiety benefited more (Pae 2015).

  • Sex: Women made up 65% of trial participants, yet few trials analyzed results by sex, per a systematic review (Santos-Casado 2021); no sex difference in benefit has been established.

  • Age: Benefit was shown in a trial with a mean age of 70.6 years (Katona 2012), but a post-hoc (after-the-fact) analysis of a pragmatic (real-world) late-life trial found no advantage over SSRIs in moderate-to-severe depression (Bartoli 2025).

  • Pre-existing conditions: Benefit is established in adult MDD, including people reporting cognitive complaints (Mahableshwarkar 2015); two pediatric trials were negative (Trintellix label), and in depressed Alzheimer’s patients a placebo-controlled trial partly funded by Lundbeck Korea found no benefit (Jeong 2022).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Nausea and Other Gastrointestinal Effects

Nausea is the most common adverse effect: dose-related, usually mild to moderate, most frequent in the first week, with a median duration of two weeks and higher rates in women (Trintellix label); vomiting, constipation, dry mouth and flatulence also increase (Trintellix label). Gut serotonin stimulation is the likely mechanism. Beyond the Takeda label data, the Lundbeck trial in older adults (Katona) found nausea in 21.8% versus 8.3% with placebo (Katona 2012), and the independent Cochrane review (Koesters) found more dropouts due to adverse effects than with placebo (Koesters 2017).

Magnitude: Nausea in 21% (5 mg), 26% (10 mg) and 32% (15–20 mg) versus 9% with placebo (Trintellix label); vomiting in 3–6% versus 1% (Trintellix label); diarrhea in 7–10% versus 6% (Trintellix label); dry mouth in 6–8% versus 6% (Trintellix label); discontinuation for adverse effects RR (risk ratio, the risk relative to placebo) 1.41 (95% CI 1.09 to 1.81), 53 versus 38 per 1,000 (Koesters 2017).

Medium 🟥 🟥

Sexual Dysfunction ⚠️ Conflicted

In seven placebo-controlled trials using the ASEX (Arizona Sexual Experiences Scale), treatment-emergent sexual dysfunction rose with dose in people with normal baseline function (Trintellix label). Serotonin-driven inhibition of desire and orgasm is the presumed mechanism. A Takeda trial in healthy adults found significant sexual impairment versus placebo with paroxetine but not with vortioxetine (Jacobsen 2019). Net reading: the risk is modest at 5–10 mg, rises at 20 mg, and was lower than with paroxetine in direct comparison.

Magnitude: At 20 mg, 34% of women and 29% of men developed sexual dysfunction versus 20% and 14% with placebo (Trintellix label).

Dizziness, Itching and Abnormal Dreams

Dizziness, pruritus (itching, including generalized itching) and abnormal dreams occurred slightly more often with vortioxetine than with placebo in pooled Takeda and Lundbeck short-term trials (Trintellix label). No mechanism has been established. A sponsor meta-analysis (Baldwin) listed dizziness among the most common adverse events, yet only nausea reached at least twice the placebo rate (Baldwin 2016).

Magnitude: Dizziness in 6–9% versus 6% with placebo (Trintellix label); pruritus in 1–3% versus 1% with placebo (Trintellix label); abnormal dreams in 2–3% at 15–20 mg versus 1% with placebo (Trintellix label).

Low 🟥

Suicidal Thoughts in Young Adults ⚠️ Conflicted

A boxed warning (the most prominent US label warning), based on pooled trials of other antidepressants, reports more suicidal thoughts and behaviors under age 25 (Trintellix label). A Takeda post hoc (after-the-fact) pooled analysis of vortioxetine trials found no increase (Mahableshwarkar 2020). Net reading: the class risk applies by inference.

Magnitude: Across antidepressants, 5 additional patients per 1,000 aged 18–24 versus placebo (Trintellix label); in vortioxetine trials, suicide-related adverse events in 0.2–1.0% versus 0.4% with placebo (Mahableshwarkar 2020).

Discontinuation Symptoms ⚠️ Conflicted

Abruptly stopping 15–20 mg caused headache, muscle tension, mood swings, anger outbursts, dizziness and runny nose in some trial patients during the first week (Trintellix label). A sponsor pooled analysis found total discontinuation scores comparable to placebo (Baldwin 2016). Net reading: the excess over placebo is small.

Magnitude: In the first week after abrupt stopping, DESS (Discontinuation-Emergent Signs and Symptoms checklist) total score 1.41–1.58 with 10–20 mg versus 0.96 with placebo, not compared between groups (Baldwin 2016); in a chart review, discontinuation symptoms in 3% of 263 patients, no control group (Siwek 2021).

Hyponatremia

Hyponatremia (low blood sodium) can occur, often through SIADH (syndrome of inappropriate antidiuretic hormone, in which the body retains excess water) (Trintellix label); older adults and diuretic (urine-increasing drug) users face higher risk (Trintellix label). A 74-year-old man developed SIADH one week after starting vortioxetine (Sasaki 2024).

Magnitude: Not quantified in available studies. The evidence consists of case reports and one premarketing case, with no controlled incidence figure.

Bleeding

Drugs blocking serotonin reuptake are linked to bleeding, from bruising to life-threatening hemorrhage, especially with NSAIDs (anti-inflammatory pain relievers such as ibuprofen), aspirin or anticoagulants (drugs that slow clotting) (Trintellix label). Platelet serotonin depletion is the proposed mechanism. One case report showed recurrence on rechallenge (restarting the drug) (Lee 2024).

Magnitude: Not quantified in available studies. No study has measured a vortioxetine-specific bleeding rate; the warning rests on SSRI and SNRI class data.

Serotonin Syndrome

Serotonin syndrome (agitation, fever, tremor and muscle rigidity from excess serotonin) can occur alone and especially with other serotonergic drugs (Trintellix label). In an analytically confirmed 1,260 mg overdose, no serotonin toxicity developed (Daneshmend 2024).

Magnitude: Not quantified in available studies. No trial or cohort has reported an incidence; the evidence is the label’s class warning and case reports.

Mania or Hypomania

In bipolar disorder, antidepressant treatment may trigger a mixed (simultaneous manic and depressive symptoms) or manic episode (Trintellix label). Case reports describe vortioxetine-induced hypomania (a milder form of mania) (Tunc 2022).

Magnitude: Mania or hypomania in fewer than 0.1% of premarketing patients; the label reports no placebo rate (Trintellix label).

Angle-Closure Glaucoma ⚠️ Conflicted

Antidepressant-induced pupil dilation may trigger angle-closure glaucoma (sudden blockage of the eye’s fluid drainage) in people with untreated narrow angles (a tight eye drainage channel) (Trintellix label). An observational SSRI meta-analysis found larger pupils but no higher glaucoma risk (Wang 2018). Net reading: the risk mainly concerns this anatomy.

Magnitude: Not quantified in available studies. No vortioxetine-specific incidence has been reported; the warning is a class effect.

Hypersensitivity Reactions

Anaphylaxis (severe whole-body allergic reaction), angioedema (swelling of the deeper skin layers) and urticaria (hives) have been reported with vortioxetine (Trintellix label). In global post-marketing reports, hypersensitivity and skin reactions formed one of the two largest clusters (Ekhart 2022).

Magnitude: Not quantified in available studies. The evidence is post-marketing reports of unknown frequency, with no controlled incidence figure.

Seizure, Pancreatitis, Smell Loss and Other Postmarketing Reports

Seizure, acute pancreatitis (pancreas inflammation), hyperprolactinemia (raised prolactin), aggression, agitation, hostility, irritability, anosmia (smell loss), weight gain, headache, rash and hyperhidrosis (excess sweating) appear among voluntary postmarketing reports (Trintellix label). In a case series of nine people with epilepsy, two had seizures attributed to inadequate antiepileptic treatment (Siwek 2022).

Magnitude: Not quantified in available studies. The label lists these as voluntary reports from a population of uncertain size, with no incidence figure.

Pregnancy and Newborn Effects

Serotonergic antidepressants, including vortioxetine, taken late in pregnancy may cause newborn complications and persistent pulmonary hypertension of the newborn (high lung blood pressure after birth), and raise postpartum hemorrhage (heavy bleeding after birth) risk (Trintellix label). The evidence is indirect: a meta-analysis of SSRIs, not vortioxetine (Grigoriadis 2014).

Magnitude: Late-pregnancy SSRI exposure: persistent pulmonary hypertension of the newborn odds ratio 2.50 (95% CI 1.32 to 4.73), an absolute risk difference of 2.85–3.50 per 1,000 live births against a baseline of 1.9 per 1,000 (Grigoriadis 2014).

Speculative 🟨

Rectal Adenomas in Female Rats

Benign rectal adenomas (non-cancerous growths) increased in female rats at 39 times the maximum recommended human dose, which the label links to inflammation (Trintellix label). The basis is animal data only.

Risk-Modifying Factors

  • CYP2D6 status: Poor metabolizers reach higher levels (Trintellix label), as do people taking bupropion, which raised vortioxetine exposure by 128% in a Takeda interaction study (Chen 2013), raising the likelihood of nausea and other dose-related effects.

  • Baseline sodium and fluid status: Older age, diuretic use and volume depletion (low body fluid) increase hyponatremia risk (Trintellix label); a low-normal baseline sodium leaves less margin.

  • Sex: Nausea is more common in women (Trintellix label); sexual dysfunction at 20 mg affected 34% of women and 29% of men (Trintellix label).

  • Age: In adults 60 and older, a meta-analysis found side effects and dropouts matched serotonin reuptake inhibitors (Rodrigues Alessi 2025); older adults carry higher hyponatremia risk (Trintellix label), and the suicidality signal concerns people under 25 (Trintellix label).

  • Pre-existing conditions: Personal or family history of bipolar disorder, untreated narrow angles and use of anticoagulants raise specific risks (Trintellix label); kidney or liver impairment did not alter exposure meaningfully in Takeda pharmacokinetic (drug-level) studies (Chen 2018).

Key Interactions & Contraindications

Documented interactions:

  • MAOIs (monoamine oxidase inhibitors, drugs blocking a serotonin-degrading enzyme: phenelzine, tranylcypromine, isocarboxazid, selegiline, linezolid, intravenous methylene blue): risk of serotonin syndrome. Contraindicated: no MAOI within 21 days after stopping vortioxetine, and no vortioxetine within 14 days after stopping an MAOI (Trintellix label).

  • Other serotonergic drugs (SSRIs such as sertraline, SNRIs such as duloxetine, triptans (migraine drugs) such as sumatriptan, tricyclics (older antidepressants) such as amitriptyline, tramadol, fentanyl, lithium, buspirone, amphetamines): higher serotonin syndrome risk; monitored for agitation, tremor and fever (Trintellix label).

  • Strong CYP2D6 inhibitors (bupropion, fluoxetine, paroxetine, quinidine): raise vortioxetine levels (Trintellix label), increasing nausea risk; bupropion raised exposure by 128% (Chen 2013). The label halves the vortioxetine dose (Trintellix label).

  • Strong CYP inducers (drugs speeding up liver enzymes: rifampin, carbamazepine, phenytoin): lower vortioxetine levels (Trintellix label), risking lost effect; rifampicin cut exposure by 72% (Chen 2013). After 14 days of co-use the dose may rise to at most three times the original (Trintellix label).

  • Antiplatelet drugs (which stop platelets clumping) and anticoagulants (aspirin, clopidogrel, heparin, warfarin): possible added bleeding risk; INR (international normalized ratio, a clotting test) monitored with warfarin (Trintellix label). A Takeda study found no drug-level (pharmacokinetic) or platelet interaction with aspirin or warfarin (Chen 2015).

  • Over-the-counter NSAIDs (ibuprofen, naproxen, aspirin): added risk of gastrointestinal and other bleeding (Trintellix label); occasional short courses taken with food limit exposure.

  • Supplements: St. John’s wort and tryptophan: additive serotonergic activity raising serotonin syndrome risk (Trintellix label); the combination is avoided or used with symptom monitoring.

  • Diuretics (hydrochlorothiazide, furosemide): increase hyponatremia risk (Trintellix label); sodium is checked after starting.

  • Alcohol, diazepam and lithium: no interaction found on drug levels, or on psychomotor performance (reaction speed and coordination) with alcohol or diazepam, in a Takeda study of healthy volunteers (Chen 2016).

  • Ketoconazole and fluconazole: modest increases in vortioxetine exposure (30% and 46%) (Chen 2013), with possible extra nausea; no interaction found with ethinyl estradiol/levonorgestrel contraceptives or omeprazole (Chen 2013).

  • Methadone urine screens: vortioxetine can cause false-positive methadone results on standard urine immunoassays (antibody-based screening tests) (Trintellix label); confirmatory testing resolves this.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • 5-HTP (5-hydroxytryptophan) and SAMe (S-adenosylmethionine): inferred from additive serotonergic activity; possible serotonin syndrome. Avoiding these supplements during treatment removes the concern.

  • Dextromethorphan (over-the-counter cough suppressant): inferred from additive serotonergic activity; possible agitation, tremor or fever. Non-serotonergic cough remedies avoid the overlap.

  • High-dose fish oil, ginkgo and curcumin: inferred from additive antiplatelet effects; possible increased bruising or bleeding, mainly relevant when anticoagulants or NSAIDs are also used.

  • Cannabidiol: inferred from its inhibition of CYP2D6 and CYP3A4 in laboratory studies; possible higher vortioxetine levels and more nausea. Starting cannabidiol at a low dose limits the effect.

Populations who should avoid Vortioxetine:

  • People taking an MAOI for psychiatric disorders or within 14 days of stopping one, or being treated with linezolid or intravenous methylene blue (Trintellix label)
  • People with known hypersensitivity to vortioxetine; anaphylaxis (severe whole-body allergic reaction) and angioedema (swelling of the deeper skin layers) have been reported (Trintellix label)
  • Children and adolescents aged 7–17 years, in whom two trials showed no benefit over placebo (Trintellix label)
  • People with untreated anatomically narrow angles without a patent iridectomy (an opening made in the iris) (Trintellix label)
  • People with unscreened or untreated bipolar disorder, in whom a manic or mixed episode may be triggered (Trintellix label)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Lower starting dose for older adults: a 5 mg starting dose from age 65 (EMA SmPC Brintellix) reduces early nausea and dizziness; taking the dose with food during the first two weeks also eases nausea.

  • Sodium checks in higher-risk users: serum sodium at baseline and 2–4 weeks after starting in adults over 65 or on diuretics detects hyponatremia early. Symptomatic hyponatremia leads to stopping vortioxetine (Trintellix label).

  • Genotype-aware dosing: a 10 mg maximum for CYP2D6 poor metabolizers and halving the dose with strong CYP2D6 inhibitors (Trintellix label) prevent excess exposure and dose-related nausea.

  • Step-down before stopping: reducing 15–20 mg to 10 mg for one week before stopping (Trintellix label) limits discontinuation symptoms such as irritability and headache.

  • Bleeding precautions: monitoring INR when warfarin is started, dose-adjusted or stopped alongside vortioxetine (Trintellix label) and limiting regular NSAID use reduce bleeding risk.

  • Bipolar screening and early follow-up: screening for personal or family bipolar history before starting and watching for mood worsening or suicidal thoughts in the first months and after dose changes (Trintellix label) addresses mania and suicidality risks.

  • Dose matching for sexual side effects: because sexual dysfunction rises at 20 mg (Trintellix label), staying at 10 mg when it controls symptoms limits this risk.

  • No serotonergic supplement stacking: stopping 5-HTP, tryptophan and St. John’s wort before starting reduces serotonin syndrome risk.

  • Eye check when narrow angles are suspected: an ophthalmology review before starting in people with prior angle-closure symptoms or known narrow angles lowers the risk of angle-closure glaucoma.

Therapeutic Protocol

Timing, titration steps (stepwise dose increases) and other parameters without a citation reflect common practice; each dose is cited to its source.

  • Standard label regimen: 10 mg once daily, increased to 20 mg as tolerated; 5 mg for people who do not tolerate higher doses (Trintellix label).

  • European older-adult regimen: 5 mg starting dose from age 65, with continuation for at least six months after symptoms resolve (EMA SmPC Brintellix).

  • Late-life depression trial regimen: 5 mg daily for 8 weeks in adults with a mean age of 70.6 years (Katona 2012).

  • Cognitive-training regimen (Lenze, Washington University): 10 mg daily for 26 weeks combined with computerized cognitive training in adults 65 and older with age-related cognitive decline (Lenze 2020).

  • Dose-response: a dose-response meta-analysis estimated the near-maximal effective dose at 17.93 mg/day, with no plateau evident at 20 mg (Yang 2024).

  • Competing approaches: generic SSRIs such as sertraline performed similarly in moderate-to-severe late-life depression in a post-hoc trial analysis (Bartoli 2025); psychotherapy and structured exercise are alternative or combined options.

  • Time of day: once daily with or without food (Trintellix label); evening dosing is commonly used when nausea is troublesome, morning dosing when vivid dreams occur.

  • Half-life and dosing pattern: a 66-hour half-life (Trintellix label) and steady state within two weeks (Trintellix label) support a single daily dose; split dosing offers no advantage.

  • Genetic polymorphisms: CYP2D6 poor metabolizers are limited to 10 mg daily (Trintellix label); ultrarapid metabolizers (people with extra-active CYP2D6) may need the upper dose range.

  • Sex: exposure did not differ meaningfully between men and women, so no sex-based dose adjustment applies (Chen 2018); women’s higher nausea rates favor slower titration.

  • Age: exposure is similar in older and younger adults (Chen 2018), but the European product information starts at 5 mg from age 65 (EMA SmPC Brintellix).

  • Baseline biomarkers: a low-normal sodium favors closer early sodium checks; in post-COVID-19 condition, higher baseline CRP predicted cognitive response (McIntyre 2024).

  • Pre-existing conditions: no dose change for kidney or liver impairment (Chen 2018); bipolar history raises the risk of an antidepressant-triggered manic or mixed episode (Trintellix label).

Discontinuation & Cycling

  • Duration: vortioxetine is used long term for recurrent depression; the EMA advises continuing at least six months after symptoms resolve (EMA SmPC Brintellix), and a placebo-controlled maintenance study ran 24–64 weeks (Trintellix label).

  • Withdrawal effects: headache, muscle tension, mood swings, anger outbursts and dizziness after abrupt stops from 15–20 mg (Trintellix label); symptoms were more frequent after accidental, unsupervised stops (Siwek 2021).

  • Tapering: 15–20 mg is reduced to 10 mg for one week before stopping (Trintellix label); the long half-life provides a natural gradual decline after the last dose.

  • Cycling: no study has tested cycling, and no loss of effect requiring drug holidays has been described; planned interruptions expose people to the relapse risk shown below.

  • Relapse after stopping: in remitted patients switched to placebo, 26% relapsed versus 13% continuing vortioxetine (Boulenger 2012).

Sourcing and Quality

  • Prescription-only drug: vortioxetine is dispensed by licensed pharmacies as Trintellix (Takeda) in the US (Trintellix label) and Brintellix in the EU (EMA SmPC Brintellix); supplement-style third-party testing does not apply.

  • Formulations: US tablets come in 5, 10 and 20 mg (Trintellix label); the EU also has a 15 mg tablet and 20 mg/mL oral drops (EMA SmPC Brintellix), useful for fine dose steps.

  • Generic versions: one generic vortioxetine tablet matched the reference product in a bioequivalence (same blood levels) study, funded by its maker CSPC Ouyi, under fasting and fed conditions (Bai 2023).

  • Unregulated online sellers: sources without a prescription requirement carry counterfeit and dosing-accuracy risks; regulated pharmacies avoid them.

Practical Considerations

  • Time to effect: registration trials measured antidepressant benefit at 6–8 weeks, per a sponsor meta-analysis (Thase 2016); steady drug levels take about two weeks (Trintellix label), and cognitive trials assessed processing speed at 8 weeks (McIntyre 2014; Mahableshwarkar 2015).

  • Common pitfalls: stopping in the first week because of nausea, which lasts a median of two weeks (Trintellix label); adding serotonergic supplements; and expecting cognitive enhancement in healthy, non-depressed people, where no trial has shown it.

  • Regulatory status: approved by the FDA (Trintellix label) and the EMA (EMA SmPC Brintellix) for adult major depression only; use for cognition, anxiety or post-COVID-19 condition is off-label.

  • Cost and payer incentives: brand vortioxetine costs far more than generic SSRIs where no generic exists; insurers often require prior SSRI failure, a payer incentive that can shape guidelines and research toward cheaper generics.

Interaction with Foundational Habits

  • Sleep: Direct effect. Vortioxetine delayed and shortened REM (rapid eye movement, the dreaming stage) sleep in healthy men in a Lundbeck-sponsored study (Wilson 2015), consistent with serotonin’s suppression of REM sleep, and abnormal dreams occurred in 2–3% at 15–20 mg versus 1% with placebo (Trintellix label); morning dosing is common when dreams disturb sleep.

  • Nutrition: No interaction. Food does not change absorption (Trintellix label), and body weight did not change in placebo-controlled trials (Trintellix label). Alcohol did not alter levels or psychomotor performance (Chen 2016), though it can worsen depression; tryptophan supplements are avoided.

  • Exercise: No studied interaction. Vortioxetine had no clinically significant effect on blood pressure or heart rate (Trintellix label), so training capacity is not expected to change; early nausea may favor exercising before the daily dose.

  • Stress management: Indirect, potentiating. Vortioxetine reduced anxiety scores in depression with high anxiety in a sponsor meta-analysis (Baldwin 2016), likely through serotonergic dampening of stress reactivity; combining it with psychotherapy or mindfulness training is common practice, but no trial has tested these pairings.

Monitoring Protocol & Defining Success

Before starting, baseline testing includes a depression questionnaire (PHQ-9, the Patient Health Questionnaire-9), a timed processing-speed test such as the DSST, serum sodium for adults over 65 or diuretic users, a screen for personal or family bipolar history, a medication and supplement review for serotonergic or CYP2D6-interacting agents, and CYP2D6 genotype where available. People on warfarin have INR checked when vortioxetine is started, titrated or stopped.

Ongoing monitoring follows this cadence: symptom questionnaires at 2, 4 and 8 weeks, then every 3 months; sodium at 2–4 weeks in higher-risk users and again after dose increases; a repeat processing-speed test at 8 weeks and every 6–12 months; and a brief sexual-function review at each visit. Success is a sustained drop in depression score into the minimal range with stable or improved thinking speed and tolerable side effects.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum sodium 135–145 mmol/L (standard reference range) Safety check: detects drug-induced hyponatremia No fasting needed; pair with serum osmolality (blood concentration) if low; risk highest in older adults and diuretic users (Trintellix label)
PHQ-9 score Below 5, the minimal-symptom band (Kroenke 2001) Marker expected to change: tracks depressive symptoms Scores of 5, 10, 15 and 20 mark mild, moderate, moderately severe and severe depression (Kroenke 2001); self-completed, any time of day
DSST score No established target; track change from the individual’s own baseline Marker expected to change: processing speed Same test version and time of day each time; the label cites a mean of 50 for healthy 45–54-year-olds (Trintellix label)
CYP2D6 genotype No established target; record metabolizer status Safety check: poor metabolizers are limited to 10 mg One-time test; poor metabolizers have about twice the plasma level (Trintellix label)

Qualitative markers:

  • Mood, motivation and interest in usual activities
  • Mental sharpness, focus and word-finding
  • Nausea, appetite and bowel habits in the first weeks
  • Sleep quality and dream intensity
  • Sexual desire, arousal and orgasm
  • Energy levels and emotional range, including any sense of emotional flatness

Emerging Research

  • Frontotemporal dementia trial: A Johns Hopkins, Lundbeck-supported phase 2 (mid-stage efficacy) uncontrolled study (NCT06604520) of 50 adults with early behavioral-variant frontotemporal dementia (dementia affecting personality and behavior) measures brain glucose metabolism on PET at 12 weeks; recruiting, completion expected 2029. A positive result would extend the brain-protective case; a null result would weaken it.

  • Glioblastoma repurposing trial: The University of Zurich phase 2 ReVoGlio trial (NCT07284628) gives vortioxetine to 78 patients with newly diagnosed glioblastoma, measuring progression-free survival (time without tumor growth); recruiting. A positive result would add an anticancer dimension; a null result would confine the laboratory signal (Lee 2024) to animals.

  • Parkinson’s freezing-of-gait trial: An open-label (treatment known to all) phase 4 (post-approval) study (NCT06805266) in 40 depressed people with Parkinson disease tests freezing of gait (sudden inability to step) at 12 weeks; not yet recruiting at last update. A positive result would suggest motor benefits; a null result would leave only mood benefits.

  • Prevention of age-related cognitive decline: Lenze’s trial showed only a transient advantage (Lenze 2020), while a secondary imaging analysis, partly funded by Takeda, reported preserved brain-network segregation (the separation of distinct brain networks that blurs with age) (Waring 2023); larger, longer trials could confirm or refute a protective effect.

  • Inflammation-guided use: A higher-CRP subgroup showed cognitive benefit in post-COVID-19 condition (McIntyre 2024), but CRP did not guide anti-inflammatory add-on response in depression (Baune 2021); stratified trials would test whether inflammation predicts benefit.

  • Doses above 20 mg: A dose-response meta-analysis found no plateau at 20 mg (Yang 2024); trials of higher doses could show added benefit or reveal more nausea and sexual dysfunction.

  • Comparative effectiveness in older adults: A post-hoc analysis of a pragmatic late-life trial found no advantage over SSRIs in moderate-to-severe depression (Bartoli 2025), weakening the case for preferring vortioxetine over cheaper generics on efficacy alone.

Conclusion

Vortioxetine is a prescription antidepressant that blocks serotonin recycling and acts on several serotonin receptors. For health-focused adults, its clearest value is in treating major depression and lowering the chance of relapse, with an effect similar in size to other modern antidepressants and stronger evidence than for any other use. Its second claim, faster thinking and better attention during depression, is supported by several manufacturer-funded trials and combined reviews of trials, but results outside depression, in older adults with normal age-related decline and in people with lingering illness after coronavirus infection, have been mixed. Lower sexual side effects than some older antidepressants are suggested by trials from a single sponsor. Brain-protective and anticancer effects remain laboratory findings.

The main costs are early nausea, dose-related sexual problems, and the warnings shared with other serotonin drugs: low blood sodium in older adults, bleeding with blood-clotting medicines, dangerous reactions when combined with other serotonin-raising drugs or supplements, and possible mood swings in undiagnosed bipolar disorder. A gene that controls how fast the body clears the drug changes how much reaches the blood.

The evidence base is large for depression but mostly produced by the companies that market the drug, and independent reviewers judged its quality low. For adults focused on a long, healthy life, vortioxetine is a well-studied option when depression is present, while its value as a tool for keeping the brain sharp in healthy aging remains unproven.

Top - Benefits - Risks - Protocol